WO2025022178 - IN-SITU MRNA VACCINE PRODUCTION METHOD AND DEVICE

National phase entry is expected:
Publication Number WO/2025/022178
Publication Date 30.01.2025
International Application No. PCT/IB2024/000418
International Filing Date 24.07.2024
Title [English] IN-SITU MRNA VACCINE PRODUCTION METHOD AND DEVICE [French] PROCÉDÉ ET DISPOSITIF DE PRODUCTION DE VACCIN À ARNM IN SITU
Applicants ** APTE, Zachary, Schulz Friedrichstr 114A 10117 Berlin, DE
Inventors ** APTE, Zachary, Schulz Friedrichstr 114A 10117 Berlin, DE
Priority Data 63/528,429  24.07.2023  US
front page image
Application details
International Searching Authority
Translation

Recalculate

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country Stages Total
China Filing 2447
EPO Filing, Examination 29315
Japan Filing 574
South Korea Filing 578
USA Filing, Examination 12035
+ Add country
MasterCard Visa
Total: 44949
QUOTE TO EMAIL ONLINE QUOTE
Abstract [English] The present invention relates to an in-situ device for producing nucleic acid-based vaccines and therapeutics, particularly RNA vaccines. The device integrates multiple steps of vaccine production, including DNA transcription into RNA, RNA purification, and RNA encapsulation in a lipid carrier, into a single automated unit. This approach reduces contamination risk and allows rapid, scalable production of vaccines, facilitating immediate responses to emerging infectious diseases and simplifying logistics by producing vaccines close to the point of care. [French] La présente invention concerne un dispositif in situ permettant de produire des vaccins et des agents thérapeutiques à base d'acide nucléique, en particulier des vaccins à ARN. Le dispositif intègre de multiples étapes de production de vaccin, comprenant la transcription d'ADN en ARN, la purification d'ARN et l'encapsulation d'ARN dans un vecteur lipidique, en une seule unité automatisée. Cette approche réduit le risque de contamination et permet une production rapide et évolutive de vaccins, facilitant des réponses immédiates à des maladies infectieuses émergentes et simplifiant la logistique par production des vaccins proches du point d'intervention.